| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1470-2045(14)71183-0 |
| P698 | PubMed publication ID | 25524799 |
| P2093 | author name string | Xavier Thomas | |
| P2860 | cites work | Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab | Q34627748 |
| Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study | Q43889424 | ||
| Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. | Q46174384 | ||
| Treatment of adult acute lymphoblastic leukemia | Q46187922 | ||
| Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies | Q83733166 | ||
| P433 | issue | 1 | |
| P921 | main subject | blinatumomab | Q410189 |
| P304 | page(s) | 6-7 | |
| P577 | publication date | 2014-12-16 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | Blinatumomab: a new era of treatment for adult ALL? | |
| P478 | volume | 16 |
| Q28066316 | Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor |
| Q38588912 | Blinatumomab for the treatment of acute lymphoblastic leukemia |
| Q38673606 | Blinatumomab: A novel, bispecific, T-cell engaging antibody |
| Q64053139 | Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma |
| Q92538521 | Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia |
| Q64985597 | New insights into effective targeted therapy for the treatment of adult acute lymphoblastic leukemia. |
| Q35799427 | Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia. |
Search more.